Close Menu
Home › Thermo Fisher, NX Prenatal Partner on Pregnancy Outcome Assay Development

Thermo Fisher, NX Prenatal Partner on Pregnancy Outcome Assay Development

Apr 16, 2019
|
staff reporter

NEW YORK (GenomeWeb) — Thermo Fisher Scientific and NX Prenatal said today that they have partnered on the development of mass spectrometry-based proteomics assays for adverse pregnancy outcomes.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of   FLT3  and  CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Molecular Diagnostics

  1. Qiagen Says It Is Fielding Acquisition Offers

  2. Employee Benefits Programs Share Early Experiences Implementing Genetic Testing

    Premium

  3. Centogene to Provide Diagnostic Testing Services for PTC Therapeutics Gene Therapy Program

  4. Qiagen Upgraded to Overweight by JP Morgan; Stock Surges on Thermo Fisher Buyout Speculation

  5. Exact Sciences Sues Johns Hopkins University for 'Improperly' Demanding Royalties

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.